Acetyl-L-Carnitine for Age-Related Cognitive Decline

Mixed results in healthy adults but more consistently positive outcomes in elderly populations with existing cognitive concerns. Used as a prescription drug in some European countries for cognitive impairment.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'braincited.com'; const params = 'ingredient\u003Dacetyl\u002Dl\u002Dcarnitine\u0026condition\u003Dcognitive\u002Ddecline'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

The Bottom Line

Key Study Findings

Randomized Controlled Trial

Comparative study of choline alfoscerate as a combination therapy with donepezil: A mixed double-blind randomized …

Dose: None vs: None Outcome: Cognitive decline Effect: None None

Population: Alzheimer's disease patients

Systematic Review

Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update.

Dose: None vs: None Outcome: None Effect: None None

Population: None

Review

Chronic pain and adult hippocampal neurogenesis: translational implications from preclinical studies.

Dose: None vs: None Outcome: None Effect: None None

Population: Chronic pain patients (preclinical review)

Review

Alpha-synuclein, epigenetics, mitochondria, metabolism, calcium traffic, & circadian dysfunction in Parkinson's disease. An integrated strategy …

Dose: None vs: None Outcome: None Effect: None None

Population: Parkinson's disease patients

Controlled Clinical Trial

Effect of mitochondrial cofactors and antioxidants supplementation on cognition in the aged canine.

Dose: mitochondrial cofactors + antioxidants vs: control diet Outcome: cognitive function in aged dogs Effect: improved learning and memory None

Population: Aged beagle dogs

Randomized Controlled Trial n=106 Double-blind

A Phase II Randomized Clinical Trial of a Nutritional Formulation for Cognition and Mood in …

Dose: None vs: placebo Outcome: None Effect: None p = 0.0083

Population: Alzheimer's disease patients

Key Statistics

Studies

1000

Participants

↑

Positive

Grade

Referenced Papers

Comparative study of choline alfoscerate as a combination therapy with donepezil: A mixed double-blind randomized controlled and open-label observation trial. RCT

Medicine 2024 3 citations

Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update. Review

Nutrients 2020 72 citations

Alpha-synuclein, epigenetics, mitochondria, metabolism, calcium traffic, & circadian dysfunction in Parkinson's disease. An integrated strategy for management. Review

Ageing research reviews 2017 56 citations

Chronic pain and adult hippocampal neurogenesis: translational implications from preclinical studies. Other

Journal of pain … 2017 49 citations

Effect of mitochondrial cofactors and antioxidants supplementation on cognition in the aged canine. Other

Neurobiology of aging 2016 19 citations

A Phase II Randomized Clinical Trial of a Nutritional Formulation for Cognition and Mood in Alzheimer's Disease. RCT

Journal of Alzheimer's … 2015 112 citations

Pharmacological interventions for cognitive decline in people with Down syndrome. Meta-Analysis

The Cochrane database … 2015 33 citations

n-3 polyunsaturated fatty acids supplementation enhances hippocampal functionality in aged mice. Other

Frontiers in aging … 2014 111 citations

A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia. RCT

The journal of … 2010 70 citations

Dietary supplementation with a combination of alpha-lipoic acid, acetyl-L-carnitine, glycerophosphocoline, docosahexaenoic acid, and phosphatidylserine reduces oxidative damage to murine brain … Other

Nutrition research (New … 2009 65 citations

Alzheimer's disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention. Review

Alternative medicine review … 2008

Acetyl-L-carnitine and alpha-lipoic acid supplementation of aged beagle dogs improves learning in two landmark discrimination tests. Other

FASEB journal : … 2007 52 citations

Acetyl-L-carnitine for dementia. Systematic Review

The Cochrane database … 2003 94 citations

A review of nutrients and botanicals in the integrative management of cognitive dysfunction. Review

Alternative medicine review … 1999 112 citations

[Methodology of a clinical controlled study of L-acetylcarnitine]. CCT

La Clinica terapeutica 1990 3 citations

Pharmaco-electroencephalographic and clinical effects of the cholinergic substance--acetyl-L-carnitine--in patients with organic brain syndrome. RCT

International journal of … 1990

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Commonly Used Dosages

general:: 500-2,000 mg/day
cognitivesupport:: 1,500-3,000 mg/day

Upper limit: Well-tolerated up to 3,000 mg/day

Dosages Studied in Research

Dosage	Duration	Effect	N
None	--	Positive	--
None	--	Positive	--
None	--	Mixed	--
None	--	Mixed	--
mitochondrial cofactors + antioxidants	--	Positive	--
None	--	Positive	106
None	--	Positive	427
None	8.0 weeks	Positive	--

Best taken: Morning, on empty stomach or with meals

Safety & Side Effects

Reported Side Effects

⚠ Gastrointestinal discomfort (nausea, vomiting, diarrhea)
⚠ Fishy body odor
⚠ Restlessness or insomnia
⚠ Increased appetite

Known Interactions

● Anticoagulants (may increase bleeding risk)
● Thyroid medications (may enhance thyroid hormone effects)
● AZT (antiretroviral — may reduce neuropathy)

Tolerable upper intake: Well-tolerated up to 3,000 mg/day

Always consult your healthcare provider before starting any supplement.

Frequently Asked Questions

Does Acetyl-L-Carnitine help with Age-Related Cognitive Decline?

Based on 14 studies with 1,000 participants, there is limited but promising evidence that Acetyl-L-Carnitine may support Age-Related Cognitive Decline management. Our evidence grade is C (Some Evidence).

How much Acetyl-L-Carnitine should I take for Age-Related Cognitive Decline?

Studies have used various dosages. A commonly studied range is 500-2,000 mg/day. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Acetyl-L-Carnitine?

Reported side effects may include Gastrointestinal discomfort (nausea, vomiting, diarrhea), Fishy body odor, Restlessness or insomnia, Increased appetite. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Acetyl-L-Carnitine and Age-Related Cognitive Decline?

We rate the evidence as Grade C (Some Evidence). This rating is based on 14 peer-reviewed studies with 1,000 total participants. The overall direction of effect is positive.

Related Evidence

Other ingredients for Age-Related Cognitive Decline

Omega-3 Fatty Acids (DHA/EPA) A Phosphatidylserine B Bacopa monnieri B Vitamin B12 B Curcumin B Ginkgo biloba C

Acetyl-L-Carnitine for other conditions

Oxidative Stress & Neuroinflammation C

Quick Verdict

Evidence Strength52%

Moderate confidence

Study Breakdown

RCT (4)Meta (1)Other (9)

Compare Alternatives

See how other ingredients compare for this condition.

View all ingredients for Age-Related Cognitive Decline

Learn More

FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. The products and information on this website are not intended to diagnose, treat, cure, or prevent any disease. The evidence grades presented are based on our analysis of published peer-reviewed research and do not constitute medical advice. Always consult your healthcare provider before starting any supplement regimen.